Survival and clinical prognostic factors in metastatic non-clear cell renal cell carcinoma treated with targeted therapy: A multi-institutional, retrospective study using the Korean metastatic renal cell carcinoma registry

Jung Kwon Kim1 | Sung Han Kim2 | Mi Kyung Song3 | Jungnam Joo3 | Seong Il Seo4 | Cheol Kwak5 | Chang Wook Jeong5 | Cheryn Song6 | Eu Chang Hwang7 | Ill Young Seo8 | Hakmin Lee1 | Sung-Hoo Hong9 | Jae Young Park10 | Jinsoo Chung2

1Department of Urology, Seoul National University Bundang Hospital, Seongnam, Republic of Korea
2Department of Urology, Center for Prostate Cancer, National Cancer Center, Goyang, Republic of Korea
3Biometric Research Branch, Center for Prostate Cancer, National Cancer Center, Goyang-si, Republic of Korea
4Department of Urology, Sungkyunkwan University College of Medicine, Seoul, Republic of Korea
5Department of Urology, Seoul National University College of Medicine, Seoul, Republic of Korea
6Department of Urology, University of Ulsan College of Medicine, Seoul, Republic of Korea
7Department of Urology, Medical School, Chonnam National University, Hwasun-gun, Republic of Korea
8Department of Urology, Wonkwang University School of Medicine and Hospital, Iksan, Republic of Korea
9Department of Urology, Seoul St. Mary's Hospital, The Catholic University, Seoul, Republic of Korea
10Department of Urology, Korea University Ansan Hospital, Korea University College of Medicine, Ansan, Republic of Korea

Abstract

Objectives: The optimal treatment strategy for metastatic non-clear cell renal cell carcinoma (mNCCRCC) is still elusive and mainly extrapolated from evidence available for metastatic clear cell renal cell carcinoma. The aim of the study was therefore to investigate the survival outcomes and prognostic factors affecting survival in patients with mNCCRCC treated with targeted therapy.

Materials and methods: We analyzed a total of 156 patients (8.1%) with mNCCRCC among the total cohort of 1922 patients in the Korean metastatic RCC registry. We used Kaplan-Meier curve analysis to calculate the survival estimates for first-line progression-free survival (PFS), total PFS, and cancer-specific survival (CSS). We also used the log-rank test to compare the different groups and multivariate Cox-proportional hazard regression analyses to evaluate the prognostic factors for survival.

Results: The mNCCRCC group had significantly inferior survival outcomes in terms of first-line PFS, total PFS, and CSS (all \( P < 0.05 \)). We found survival benefits in patients treated with first-line vascular endothelial growth factor-tyrosine kinase inhibitors (VEGF-TKIs, first-line PFS, and total PFS, all \( P < 0.05 \), cytoreductive
In field of urologic cancer, renal cell carcinoma (RCC) is a common malignancy with the annual diagnosis of over 65,000 cases in the United States. Among these RCCs, metastasis was observed in 20%-30% of cases during follow-up, even in localized RCCs underwent curative treatment. According to the 2004 World Health Organization (WHO) classification system, the most common type of RCC is clear cell RCC (CCRCC, 70%-85%). The remaining subtypes comprise papillary, chromophobe, collecting duct, unclassified, and Xp11.2 transposition; they are often classified as non-clear cell RCC (NCCRCC).

Metastatic NCCRCC (mNCCRCC) includes heterogeneous subgroups that profoundly differ in terms of morphology, genetic profile, clinical characteristic, and prognosis. The optimal treatment strategy for mNCCRCC is still elusive and mainly extrapolated from evidence available for mCCRCC. Thus, the optimal treatment strategy is represented by novel agents that target the members of vascular endothelial growth factor (VEGF) and the mammalian target of rapamycin (mTOR) pathways. Due to the rarity of NCCRCC tumors, only a few prospective randomized trials have been reported so far. Consequently, the efficacy of targeted therapy (TT) remains largely unknown in the field of mNCCRCC.

The impact of ethnic differences between Asian and non-Asian populations in drug absorption and metabolism have been well established. However, these pharmacoethnic differences in response to TT are still not well recognized. Guo et al reported a distinct pattern and severity of adverse events between Asian and non-Asian patients in the subgroup analysis of the COMPARZ trial. The more prevalent adverse events were hematologic toxicity and cytopenia in Asian patients, whereas gastrointestinal toxicity was more prevalent in non-Asian patients.

Regarding an Asian population, the incidence of RCC is lower compared to worldwide data; however, the annual percentage change in RCC has been increasing gradually in Korea. In addition, there were 11.3% of patients with metastatic disease at the time of diagnosis in 2014 among these cases.

However, the majority of studies had been conducted considering mCCRCC, the predominant histologic subtype in the study cohorts. The aim of the study was therefore to investigate the survival outcomes and clinical prognostic factors affecting survival in Korean patients with mNCCRCC treated with TT.

**METHODS**

**2.1 Study cohort**

The detailed description of the Korean metastatic RCC registry has been reported in our previous study. We analyzed the data of 1922 patients who had received TT (VEGF-tyrosine kinase inhibitors [VEGF-TKIs], mTOR inhibitor [mTORi]) or cytokines as first-line treatments between 2001 and 2016. All institutions included in the study received institutional review board approval before inputting data into the registry. For consistent data collection, unified data templates were used at each institution. We retrospectively reviewed medical records and/or death certificate data to analyze survival data. As this study was carried out retrospectively, written informed consent from patients was waived. Personal identifiers were completely removed and the data were analyzed anonymously.

**2.2 Acquisition and definition of data**

The following clinicopathologic variables were collected: age at diagnosis, sex, Karnofsky performance status, Eastern Cooperative Oncology Group performance status, histologic subtypes, first-line treatment agents, the International Metastatic Renal Cell Carcinoma Database Consortium (IMDC), Memorial Sloan Kettering Cancer Center (MSKCC) risk group, metastasis details (site, synchronous, or metachronous), cytoreductive nephrectomy (CN), and metastasectomy.
Synchronous lesions were considered as metastases diagnosed at the time of diagnosis or within 3 months after primary nephrectomy; metachronous lesions were defined as recurring or progressed localized RCC that has metastasized after curative surgical treatment. Progression was defined according to radiographic criteria using the Response Evaluation Criteria in Solid Tumors (RECIST, version 1.1). We continued treatment until disease progression was detected or intolerable adverse events were reported. First-line progression-free survival (PFS) was defined as the period between the date of the first treatment and the progressive disease, and cancer-specific survival (CSS) as between the date of the first treatment and RCC-related death or the last follow-up visit. Total PFS was defined as the sum of the first line PFS and subsequent treatment PFS.

2.3 Statistical analyses

We used the Kaplan-Meier curve analysis to calculate survival estimates for first-line PFS, total PFS, and CSS. Also, we used the log-rank test to compare the different groups: CCRCC versus NCCRCC (including all histologic subtypes), VEGF-TKIs versus mTORi as the first-line treatment, synchronous versus metachronous metastasis as the metastatic type, use of CN, and metastasectomy. We performed univariate and multivariate Cox-proportional hazard regression analyses to evaluate the significant variables associated with the first-line PFS, total PFS, and CSS. We considered a two-sided p value of less than 0.05 to be statistically significant, and we performed all statistical analyses using SAS statistical software (version 9.4; SAS Institute Inc, Cary, NC) and R-project software (version 3.3.3).

3 RESULTS

The baseline characteristics are summarized in our previous study and supplemental Table S1 of the current study. A total of 156 (8.1%) patients with mNCCRCC were analyzed; these comprised 93 (59.6%) papillary, 20 (12.8%) chromophobe, 18 (11.5%) collecting duct, 16 (10.3%) unclassified, and nine (5.8%) Xp11.2 translocation RCC. Regarding the first-line therapy, majority of patients (91.0%) were treated with TT, while only 14 patients (9.0%) were treated with cytokine immunotherapy. Lymph nodes (53.3%) were reported as the most common site of metastasis, followed by the lung (46.1%), bone (42.9%), liver (26.6%), and brain (3.3%).

The survival outcomes for the mNCCRCC group were significantly inferior to those for the mCCRCC group in terms of first-line PFS (median: 5.0 vs 8.0 months, \( P = 0.0008 \)),

![Figure 1](https://example.com/figure1.png)

**FIGURE 1** Kaplan-Meier survival curves for (A) first-line progression-free survival (PFS), (B) total PFS, and (C) cancer-specific survival (CSS) for patients with clear cell and non-clear cell metastatic renal cell carcinoma.
3.1 | Comparison of survival outcomes according to the histologic subtypes

Kaplan-Meier survival analysis showed significantly favorable survival outcomes in terms of first-line PFS (median: 10.0 vs 18.0 vs 8.0 months), total PFS (median: 14.0 vs 24.0 vs 12.0 months), and CSS (median: 58.0 vs 31.0 vs 31.0 months, all respectively) in the chromophobe and Xp11.2 transposition groups compared to the clear cell group (Figure 2 and Supplemental Table S2). Conversely, survival outcomes of the papillary, collecting duct, and unclassified groups were significantly poorer than those of the clear cell group (first-line PFS, median: 4.0 vs 4.0 vs 4.0 vs 8.0 months; total PFS, median: 6.0 vs 4.0 vs 4.0 vs 12.0 months; CSS, median: 19.0 vs 35.0 vs 10.0 vs 31.0 months, all respectively).

3.2 | Comparison of survival outcomes according to the first-line treatment

Kaplan-Meier survival analysis showed that the VEGF-TKIs group (n = 79, 50.6%) had significantly better survival outcomes than the mTORi group (n = 63, 40.4%) in terms of first-line PFS (median: 8.0 vs 4.0 months, \( P = 0.0284 \)) and total PFS (median: 10.0 vs 5.0 months, \( P = 0.0275 \)). However, regarding CSS, no statistically significant difference was shown between the two groups (median: 27.0 vs 16.0 month, \( P = 0.1706 \); Figure 3).

3.3 | Comparison of survival outcomes according to the type of metastasis

Kaplan-Meier survival analysis showed that the survival outcomes the metachronous group were significantly better than those of the synchronous group in terms of first-line PFS (median: 8.0 vs 3.0 months, \( P = 0.0045 \)), total PFS (median: 10.0 vs 4.0 months, \( P = 0.0135 \)), and CSS (median: 35.0 vs 13.0 months, \( P < 0.0001 \); Figure 4).

3.4 | Comparison of survival outcomes according to the use of CN and metastasectomy

Kaplan-Meier survival analysis showed that the CSS of the CN group was significantly better than that of the non-CN group (median: 30.0 vs 6.0 months, \( P < 0.0001 \)). However, no statistically significant differences were found between the two groups in terms of first-line PFS (median: 5.0 vs 2.0 months, \( P = 0.0915 \)) and total PFS (median: 7.0 vs 2.0 months, \( P = 0.3630 \); Supplemental Figure S1). In addition, while the metastasectomy group also showed significantly

![Figure 2](image-url)  
**Figure 2** Kaplan-Meier survival curves for (A) first-line progression-free survival (PFS), (B) total PFS, and (C) cancer-specific survival (CSS) according to the histologic types.
better survival outcomes than the non-metastasectomy group in terms of CSS (median: 81.0 vs 17.0 months, \( P = 0.0017 \)), they were not significantly better in first-line PFS (median: 7.0 vs 4.0 months, \( P = 0.1325 \)) and total PFS (median: 7.0 vs 6.0 months, \( P = 0.1652 \); Supplemental Figure S2).

3.5 Prognostic factors for survival

Multivariable Cox regression analysis revealed that metachronous metastasis (hazard ratio [HR]: 0.593; 95% confidence interval [CI]: 0.357-0.986, \( P = 0.0442 \)) and liver metastasis (HR: 1.856; 95% CI: 1.228-2.805, \( P = 0.0033 \)) were significant prognostic factors for first-line PFS (Table 1). The significant prognostic factors for CSS were both the MSKCC (HR: 2.689; 95% CI: 1.116-6.387) and IMDC (HR: 2.919; 95% CI: 1.270-6.637) poor risk groups, lung (HR: 2.135; 95% CI: 1.183-3.818), liver (HR: 3.868; 95% CI: 1.713-8.205), and bone (HR: 1.630; 95% CI: 1.057-2.515) metastasis (\( P < 0.05 \); Table 2).

4 DISCUSSION

In an Asian population, this is the largest nationwide study to investigate mNCCRCC treated with TT until now. Importantly, we found that the survival outcomes of the mNCCRCC patients were inferior to those of the mCCRCC patients in the current TT era (Figure 1). Several previous studies also reported similar results regarding this issue.\(^{18,19}\) Upton et al\(^{18}\) reported that mNCCRCC showed a worse response to conventional immunotherapies than mCCRCC (overall response rate 21% vs 6%, respectively). In a recent large retrospective analysis of IMDC, Kroeger et al\(^{19}\) found that mNCCRCC patients had significantly poorer overall survival (OS) than did patients with mCCRCC treated with TT agents (12.8 vs 22.3 months; \( P < 0.0001 \)); chromophobe RCC had the best OS, and those with papillary and unclassified RCC had the worst OS. In concordance with their study, we also found significantly favorable survival outcomes in the chromophobe and Xp11.2 transposition groups compared to the clear cell group; conversely, the survival outcomes of the papillary, collecting duct, and unclassified group were significantly poorer than those of the clear cell group. With this perspective, we tentatively suggest that we need to focus more on each subtype to evaluate the individual survival outcomes.

In the field of mNCCRCC, the results of two prospective phase II randomized trials (ESPN and ASPEN) comparing the activity of the VEGF-TKIs (sunitinib) with the
mTORi (everolimus) were reported\(^5,6\); both studies demonstrated better PFS in the first-line sunitinib group than in the everolimus group (6.1 vs 4.1 months [ESPN] and 8.3 vs 5.6 months [ASPEN], respectively). However, regarding OS, the VEGF-TKIs were not superior to mTORi. Several hypotheses (including impact of subsequent treatment,\(^20\) type of the VEGF-TKI and its spectrum of molecular targets\(^21\)) have been proposed to explain the non-superiority in OS, although none of these was conclusive. Regarding the other mTORi (temsirolimus), in the previous phase III ARCC trial, Hudes et al\(^22\) reported that first-line temsirolimus offer an OS advantage compared with interferon alfa (HR: 0.73; 95% CI: 0.58-0.92; \(P = 0.008\)) in patients with metastatic RCC and a poor prognosis. In their study, they included a total of 40 mNCCRCC patients; this is still the largest study evaluating the efficacy of temsirolimus as first-line treatment in mNCCRCC.

Importantly, in the current study, the majority of patients (\(n = 47, 74.6\%\)) in the mTORi group received temsirolimus as first-line treatment (Supplemental Table S1). This reflects the largest study to date that compares the efficacy of temsirolimus with VEGF-TKIs in mNCCRCC patients as a first-line treatment. In concordance with previous studies,\(^5,6\) we also found that the VEGF-TKI group had significantly better first-line (8.0 vs 4.0 months) and total (10.0 vs 5.0 months) PFS than the mTORi group, but not CSS (Figure 3). Consequently, we tentatively concluded that the first-line VEGF-TKIs is, at present, the most recommended treatment option in patients with mNCCRCC, supporting the standard treatment paradigm broadly used for mCCRCC patients.

Generally, metachronous metastasis (MM) is considered to have a better prognosis than synchronous metastasis (SM) in the field of metastatic RCC.\(^23,24\) It can be explained by the presence or absence of primary tumors following nephrectomy, or the distinct phenotypes with different ontogenetic activities between the two groups. Kim et al\(^24\) reported that MM is associated with more favorable survival outcomes than SM in patients with metastatic RCC treated with VEGF-TKIs (OS, 20.1 vs 9.6 months, \(P = 0.010\)). In the current study, we also found that that MM had significantly better survival outcomes than SM in Kaplan-Meier survival analysis in our mNCCRCC cohort (Figure 4). However, in multivariate analysis, metastatic type was only a statistically significant prognostic factor in the first-line PFS, not in the CSS (Tables 1 and 2). This might be due to the small number of cases and uncontrolled heterogeneity of various degrees of tumor burden. Thus, further larger studies are warranted.

Regarding the surgical treatment in the field of metastatic RCC, the use of CN in patients treated with conventional immunotherapy is evident.\(^25\) Also, in a previous prospective study, Daliani et al\(^26\) evaluated the value of metastasectomy in patients receiving cytokine, tumor vaccine, and/or...
chemotherapy; they found that 29 (76%) of the 38 patients enrolled showed no evidence of disease postoperatively, and the median PFS and OS were 1.8 and 4.7 years, respectively. However, the role of CN and metastasectomy in the area of TT still needs to be defined. Recently, the randomized phase III CARMENA trial showed that sunitinib alone was not inferior to CN followed by sunitinib in patients with mCCRCC who were classified as having intermediate-risk or poor-risk disease (HR: 0.89; 95% CI: 0.71 to 1.10; upper boundary of the 95% CI for noninferiority, ≤1.20).27 The median OS for patients who received the sunitinib alone was 18.4 months, compared with 13.9 months for those who received CN followed by sunitinib. No significant differences in PFS were observed. However, in the field of mNCCRCC, these issues had not been addressed. In the current study, we found that both the CN and metastasectomy groups showed significantly better CSS than the non-CN and non-metastatectomy groups in Kaplan-Meier survival analysis (Supplemental Figures 1 and 2); however, no further differences were found between the two groups in terms of first-line PFS and total PFS. Further randomized clinical trials regarding the role of CN and metastasectomy in the field of mNCCRCC are warranted to provide more definitive results of these issues.

**TABLE 1** Cox regression analysis for first-line progression-free survival

| Variable                        | Univariate HR (95% CI) | P      | Multivariate HR (95% CI) | P      |
|---------------------------------|------------------------|--------|--------------------------|--------|
| Histology                       |                        |        |                          |        |
| Papillary                       | 1 (Ref)                |        |                          |        |
| Chromophobe                     | 0.612 (0.337-1.110)    | 0.1059 |                          |        |
| Collecting duct                 | 0.975 (0.515-1.846)    | 0.9381 |                          |        |
| Unclassified                    | 0.637 (0.303-1.340)    | 0.2348 |                          |        |
| Xp11.2 translocation            | 0.659 (0.265-1.639)    | 0.3693 |                          |        |
| Type of first-line therapy      |                        |        |                          |        |
| VEGF-TKIs                       | 1 (Ref)                |        |                          |        |
| mTORi                           | 0.584 (0.354-0.820)    | 0.0324 | 0.629 (0.410-1.184)      | 0.1954 |
| Metastasis type                 |                        |        |                          |        |
| Synchronous                     | 1 (Ref)                |        |                          |        |
| Metachronous                    | 0.591 (0.400-0.871)    | 0.0080 | 0.593 (0.357-0.986)      | 0.0442 |
| MSKCC risk group                |                        |        |                          |        |
| Favorable                       | 1 (Ref)                |        |                          |        |
| Intermediate                    | 1.250 (0.799-1.955)    | 0.3280 | 0.989 (0.576-1.699)      | 0.9689 |
| Poor                            | 2.885 (1.426-5.836)    | 0.0032 | 1.948 (0.827-4.588)      | 0.1270 |
| IMDC risk group                 |                        |        |                          |        |
| Favorable                       | 1 (Ref)                |        |                          |        |
| Intermediate                    | 1.276 (0.812-2.004)    | 0.2902 | 1.009 (0.587-1.735)      | 0.9734 |
| Poor                            | 2.879 (1.520-5.454)    | 0.0012 | 2.118 (0.980-4.578)      | 0.0563 |
| Lung metastasis, yes            | 0.823 (0.561-1.208)    | 0.3202 |                          |        |
| Liver metastasis, yes           | 1.639 (1.094-2.457)    | 0.0167 | 1.856 (1.228-2.805)      | 0.0033 |
| L/N metastasis, yes             | 1.095 (0.745-1.609)    | 0.6453 |                          |        |
| Bone metastasis, yes            | 0.888 (0.600-1.313)    | 0.5507 |                          |        |
| Brain metastasis, yes           | 0.684 (0.245-1.911)    | 0.4687 |                          |        |
| Cytoreductive nephrectomy, yes  | 0.566 (0.225-1.423)    | 0.2263 |                          |        |
| Metastasectomy, yes             | 0.707 (0.437-1.142)    | 0.1562 |                          |        |
Presently, multivariable Cox regression analysis revealed that liver metastasis was the only significant prognostic factor for both first-line PFS (HR: 1.856; 95% CI: 1.228-2.805, \( P = 0.0033 \); Table 1) and CSS (HR: 3.868; 95% CI: 1.713-8.205, \( P = 0.0007 \); Table 2). In the study of IMDC of 2027 patients with metastatic RCC, McKay et al\(^2\) reported that the presence of bone and liver metastasis in patients treated with TT confers a poor prognosis and aggressive RCC subclones tend to spread to these sites. They also demonstrated that liver metastasis was a poor prognostic factor in both PFS and OS. However, owing to the rarity of liver metastasis, a large cohort or randomized prospective study is not feasible, and the mechanism thus remains elusive. A few previous studies have hypothesized that liver metastasis occurs in association with metastases to other sites, which is in accordance with the hematogenous spread pattern observed in RCC.\(^2\) In fact, the incidence of “solitary” liver metastases in patients with mRCC has been estimated as only 2%-4%.\(^2\) Consequently, the burden of hepatic tumors could represent a rate-limiting step in terms of survival outcomes.

The current study has inevitable limitations. First, even with a large registry study design, our cohort is still relatively small due to the rarity of mNCCRCC. In addition, due to the retrospective nature, the current study is based on a highly heterogeneous study cohort (Supplemental Table S1). Another limitation of the study is the lack of a central review of pathology; subsequently, misclassification of some tumors might have affected survival outcomes. However, to the best of our knowledge, this is the largest study of mNCCRCC in an Asian population, and it can serve as support for previous results in Western populations.\(^5,6,19\) Also, the current study included the largest number of patients to date for comparing the efficacy of

|                  | Univariate HR (95% CI) | \( P \) | Multivariate HR (95% CI) | \( P \) |
|------------------|------------------------|--------|--------------------------|--------|
| **Histology**    |                        |        |                          |        |
| Papillary        | 1 (Ref)                |        | 1 (Ref)                  |        |
| Chromophobe      | 0.484 (0.254-0.920)    | 0.0268 | 0.629 (0.310-1.174)      | 0.1754 |
| Collecting duct  | 0.993 (0.523-1.887)    | 0.9829 | 0.725 (0.326-1.483)      | 0.4060 |
| Unclassified     | 1.721 (0.945-3.134)    | 0.0757 | 1.587 (0.717-3.298)      | 0.2370 |
| Xp11.2 translocation | 0.811 (0.294-2.238) | 0.6865 | 0.581 (0.171-1.574)      | 0.3322 |
| **Type of first-line therapy** |                |        |                          |        |
| VEGF-TKIs        | 1 (Ref)                |        | 1 (Ref)                  |        |
| mTORi            | 0.729 (0.410-1.221)    | 0.1853 |                         |        |
| **Metastasis type** |                    |        |                          |        |
| Synchronous      | 1 (Ref)                |        | 1 (Ref)                  |        |
| Metachronous     | 0.383 (0.255-0.577)    | <0.0001| 0.583 (0.325-1.047)      | 0.0708 |
| **MSKCC risk group** |                |        |                          |        |
| Favorable        | 1 (Ref)                |        | 1 (Ref)                  |        |
| Intermediate     | 1.762 (1.086-2.859)    | 0.0218 | 1.199 (0.675-2.142)      | 0.5425 |
| Poor             | 4.911 (2.536-9.510)    | <0.0001| 2.689 (1.116-6.387)      | 0.0277 |
| **IMDC risk group** |                |        |                          |        |
| Favorable        | 1 (Ref)                |        | 1 (Ref)                  |        |
| Intermediate     | 1.779 (1.088-2.909)    | 0.0217 | 1.184 (0.662-2.143)      | 0.5757 |
| Poor             | 4.894 (2.578-9.289)    | <0.0001| 2.919 (1.270-6.637)      | 0.0118 |
| Lung metastasis, yes | 2.279 (1.433-3.623) | 0.0005 | 2.135 (1.183-3.818)      | 0.0116 |
| Liver metastasis, yes | 3.492 (1.724-7.073) | 0.0005 | 3.868 (1.713-8.205)      | 0.0007 |
| L/N metastasis, yes | 1.944 (1.256-3.009) | 0.0028 | 1.474 (0.752-2.950)      | 0.2668 |
| Bone metastasis, yes | 1.585 (1.070-2.347) | 0.0215 | 1.630 (1.057-2.515)      | 0.0271 |
| Brain metastasis, yes | 0.576 (0.142-2.340) | 0.4408 |                       |        |
| Cytoreductive nephrectomy, yes | 0.788 (0.607-0.898) | <0.0001| 0.942 (0.743-1.180)      | 0.1190 |
| Metastasectomy, yes | 0.430 (0.249-0.744) | 0.0026 | 0.570 (0.318-1.021)      | 0.0586 |

|                  | Univariate HR (95% CI) | \( P \) | Multivariate HR (95% CI) | \( P \) |
|------------------|------------------------|--------|--------------------------|--------|
| **Lung metastasis, yes** | 2.279 (1.433-3.623) | 0.0005 | 2.135 (1.183-3.818)      | 0.0116 |
| **Liver metastasis, yes** | 3.492 (1.724-7.073) | 0.0005 | 3.868 (1.713-8.205)      | 0.0007 |
| **L/N metastasis, yes** | 1.944 (1.256-3.009) | 0.0028 | 1.474 (0.752-2.950)      | 0.2668 |
| **Bone metastasis, yes** | 1.585 (1.070-2.347) | 0.0215 | 1.630 (1.057-2.515)      | 0.0271 |
| **Brain metastasis, yes** | 0.576 (0.142-2.340) | 0.4408 |                       |        |
| **Cytoreductive nephrectomy, yes** | 0.788 (0.607-0.898) | <0.0001| 0.942 (0.743-1.180)      | 0.1190 |
| **Metastasectomy, yes** | 0.430 (0.249-0.744) | 0.0026 | 0.570 (0.318-1.021)      | 0.0586 |
temsirelimus with other agents in mNCCRCC patients as first-line treatment. Further larger studies are warranted to validate and generalize our results.

5 | CONCLUSIONS

Even with significant improvement of survival, for the majority, survival in mNCCRCC patients is still inferior to that in mCCRCC patients in the current TT era. We found survival benefits in patients treated with first-line VEGF-TKIs/CN/metastasectomy and MM patients. In addition, we demonstrated several prognostic factors for survival. Further larger studies and randomized clinical trials are needed to verify these findings.

ACKNOWLEDGMENTS

This study was supported by a grant from the Korean Urological Oncology Society 2017 research fund, Republic of Korea. We also acknowledge the Korean Renal Cell Carcinoma Study Group COHORT investigators and coordinators who collected data used in this study.

CONFLICTS OF INTEREST

The authors have no conflicts of interest to disclose.

DATA AVAILABILITY STATEMENT

The data that support the findings of this study are available from the corresponding author upon reasonable request.

ORCID

Jung Kwon Kim https://orcid.org/0000-0002-8069-6225
Eu Chang Hwang https://orcid.org/0000-0002-2031-124X
Jae Young Park https://orcid.org/0000-0002-6664-6846

REFERENCES

1. Siegel R, Naishadham D, Jemal A. Cancer statistics, 2013. CA Cancer J Clin. 2013;63:11-30.
2. Motzer RJ, Agarwal N, Beard C, et al. NCCN clinical practice guidelines in oncology: kidney cancer. J Natl Compr Canc Netw. 2009;7:618-630.
3. Lopez-Beltran A, Scarpelli M, Montironi R, Kirkali Z. 2004 WHO classification of the renal tumors of the adults. Eur Urol. 2006;49:798-805.
4. Patard JJ, Pignot G, Escudier B, et al. ICUD-EAU International Consultation on Kidney Cancer 2010: treatment of metastatic disease. Eur Urol. 2011;60:684-690.
5. Armstrong AJ, Halabi S, Eisen T, et al. Everolimus versus sunitinib for patients with metastatic non-clear cell renal cell carcinoma (ASPEN): a multicentre, open-label, randomised phase 2 trial. Lancet Oncol. 2016;17:378-388.
6. Tannir NM,Jonasch E, Albiger L, et al. Everolimus versus sunitinib prospective evaluation in metastatic non-clear cell renal cell carcinoma (ESPN): a randomized multicenter phase 2 trial. Eur Urol. 2016;69:866-874.
7. Kurose K, Sugiyama E, Saito Y. Population differences in major functional polymorphisms of pharmacokinetics/pharmacodynamics-related genes in Eastern Asians and Europeans: implications in the clinical trials for novel drug development. Drug Metab Pharmacokinet. 2012;27:9-54.
8. Mizuno T, Terada T, Kamba T, et al. ABCG2 421C>A polymorphism and high exposure of sunitinib in a patient with renal cell carcinoma. Ann Oncol. 2010;21:1382-1383.
9. Guo J, Jin J, Oya M, et al. Safety of pazopanib and sunitinib in treatment-naive patients with metastatic renal cell carcinoma: Asian versus non-Asian subgroup analysis of the COMPARZ trial. J Hematol Oncol. 2018;11:69.
10. Inada-Inoue M, Ando Y, Kawada K, et al. Phase 1 study of pazopanib alone or combined with lapatinib in Japanese patients with solid tumors. Cancer Chemother Pharmacol. 2014;73:673-683.
11. Cohen HT, McGovern FJ. Renal-cell carcinoma. N Engl J Med. 2005;353:2477-2490.
12. Joung JY, Lim J, Oh CM, et al. current trends in the incidence and survival rate of urological cancers in Korea. Cancer Res Treat. 2017;49:607-615.
13. Kim JK, Kim SH, Song MK, et al. Current trends in the incidence and survival rate of urological cancers in Korea. Cancer Res Treat. 2017;49:607-615.
14. Heng DY, Xie W, Regan MM, et al. Prognostic factors for overall survival in patients with metastatic renal cell carcinoma treated with vascular endothelial growth factor-targeted agents: results from a large, multicenter study. J Clin Oncol. 2009;27:5794-5799.
15. Heng DY, Xie W, Regan MM, et al. External validation and comparison with other models of the International Metastatic Renal-Cell Carcinoma Database Consortium prognostic model: a population-based study. Lancet Oncol. 2013;14:141-148.
16. Motzer RJ, Bacik J, Schwartz LH, et al. Prognostic factors for survival in previously treated patients with metastatic renal cell carcinoma. J Clin Oncol. 2004;22:454-463.
17. Eisenhauer EA, Therasse P, Bogaerts J, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer. 2009;45: 228-247.
18. Upton MP, Parker RA, Youmans A, et al. Histologic predictors of renal cell carcinoma response to interleukin-2-based therapy. J Immunother. 2005;28:488-495.
19. Kroege N, Xie W, Lee JH, et al. Metastatic non-clear cell renal cell carcinoma treated with targeted therapy agents: characterization of survival outcome and application of the International mRCC Database Consortium criteria. Cancer. 2013;119:2999-3006.
20. Motzer RJ, Barrios CH, Kim TM, et al. Phase II randomized trial comparing sequential first-line everolimus and second-line...
sunitinib versus first-line sunitinib and second-line everolimus in patients with metastatic renal cell carcinoma. *J Clin Oncol*. 2014;32:2765-2772.

21. Choueiri TK, Escudier B, Powles T, et al. METEOR investigators. Cabozantinib versus everolimus in advanced renal cell carcinoma (METEOR): final results from a randomised, open-label, phase 3 trial. *Lancet Oncol*. 2016;17:917-927.

22. Hudes G, Carducci M, Tomczak P, et al. Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma. *N Engl J Med*. 2007;356:2271-2281.

23. Gutenberg A, Nischwitz MD, Gunawan B, et al. Predictive chromosomal clusters of synchronous and metachronous brain metastases in clear cell renal cell carcinoma. *Cancer Genet*. 2014;207:206-213.

24. Kim SH, Suh YS, Lee DE, et al. A retrospective comparative study of progression-free survival and overall survival between metachronous and synchronous metastatic renal cell carcinoma in intermediate- or poor-risk patients treated with VEGF-targeted therapy. *Oncotarget*. 2017;8:93633-93643.

25. Flanigan RC, Mickisch G, Sylvester R, et al. Cytoreductive nephrectomy in patients with metastatic renal cancer: a combined analysis. *J Urol*. 2004;171:1071-1076.

26. Daliani DD, Tannir NM, Papandreou CN, et al. Prospective assessment of systemic therapy followed by surgical removal of metastases in selected patients with renal cell carcinoma. *BJU Int*. 2009;104:456-460.

27. Méjean A, Ravaud A, Thezenas S, et al. Sunitinib alone or after nephrectomy in metastatic renal-cell carcinoma. *N Engl J Med*. 2018;379:417-427.

28. McKay RR, Kroeger N, Xie W, et al. Impact of bone and liver metastases on patients with renal cell carcinoma treated with targeted therapy. *Eur Urol*. 2014;65:577-584.

29. Alves A, Adam R, Majno P, et al. Hepatic resection for metastatic renal tumors: is it worthwhile? *Ann Surg Oncol*. 2003;10:705-710.

30. Langan RC, Ripley RT, Davis JL, et al. Liver directed therapy for renal cell carcinoma. *J Cancer*. 2012;3:184-190.

**SUPPORTING INFORMATION**

Additional supporting information may be found online in the Supporting Information section at the end of the article.

**How to cite this article:** Kim JK, Kim SH, Song MK, et al. Survival and clinical prognostic factors in metastatic non-clear cell renal cell carcinoma treated with targeted therapy: A multi-institutional, retrospective study using the Korean metastatic renal cell carcinoma registry. *Cancer Med*. 2019;8:3401-3410. [https://doi.org/10.1002/cam4.2222](https://doi.org/10.1002/cam4.2222)